Table 2. Demographic and clinical characteristics at enrollment, DC Cohort Study, Washington, DC 2011–2016a,b.
| Analytic population | ||
|---|---|---|
| N | % | |
| Total | 8,047 | 100 |
| Age at enrollment | ||
| Median (IQR) | 47.0 (36.3, 54.6) | |
| Sex at birth | ||
| Female | 2,209 | 27.5 |
| Male | 5,838 | 72.5 |
| Race/ethnicity | ||
| Black | 6,250 | 77.7 |
| White | 1,155 | 14.4 |
| Other/Unknownb | 642 | 8.0 |
| Insurance | ||
| Private | 2,076 | 25.8 |
| Public | 5,079 | 63.1 |
| Other | 158 | 2.0 |
| Unknown | 734 | 9.1 |
| State of residence | ||
| DC | 5,994 | 74.5 |
| MD | 1,494 | 18.6 |
| VA | 453 | 5.6 |
| WV | 34 | 0.4 |
| Other/Unknown | 72 | 0.9 |
| Clinic type | ||
| Community-based | 4,282 | 53.2 |
| Hospital -based | 3,765 | 46.8 |
| Housing status | ||
| Permanent | 5,228 | 65.0 |
| Homeless/Temporary | 630 | 7.8 |
| Other/Unknown | 2,189 | 27.2 |
| HIV riskc | ||
| MSM | 3,129 | 38.9 |
| Heterosexual | 2,588 | 32.2 |
| IDU | 541 | 6.7 |
| Other | 396 | 4.9 |
| Unknown | 1,393 | 17.3 |
| AIDS diagnosis | 3,403 | 42.3 |
| CD4 count (cells/μl) | ||
| <50 | 223 | 2.8 |
| 50–199 | 663 | 8.2 |
| 200–499 | 2,752 | 34.2 |
| 500+ | 4,182 | 52.0 |
| Unknown | 227 | 2.8 |
| VL (copies/ml) | ||
| <200 200–399 00–9,999 10,000–99,9999 ≥100,000 Unknown |
5,870 227 707 675 329 239 |
72.9 2.8 8.8 8.4 4.1 3.0 |
| ARV status | ||
| Prescribed ot prescribed Unknown |
7,424 542 81 |
92.3 6.7 1.0 |
| ARV regimens among those prescribed (at enrollment) | ||
| PI-based | 2,299 | 31.0 |
| NNRTI-based | 2,107 | 28.4 |
| Dual class regimens | 676 | 9.1 |
| INSTI-based | 966 | 13.0 |
| NRTI only regimens | 166 | 2.2 |
| Triple class regimens | 149 | 2.0 |
| Other regimensd | 8 | 0.1 |
| No recorded ARV regimen at baseline | 1,053 | 14.2 |
aIncludes enrolled participants who consented as of September 30, 2016. Data reported to the DC HIV Cohort study as of December 15, 2016. Baseline demographic characteristics reflect data reported at study enrollment.
bOther race includes races reported as Hispanic, Asian, American Indian/Native American, Hawaiian/Other Pacific Islander, White-Black, and Other.
cMSM risk includes persons identified as having both MSM and injection drug use risk. Other risk includes perinatal transmission (65%), transfusion/coagulation disorder (19%), hemophiliacs and risk due to occupational exposure and other (16%).
dOther ARV regimens include TDF+FTC+MVC, 3TC+ABC+TDF+MVC, and AZT+TDF+FTC+MVC
Notes: IQR = interquartile range; NH = non-Hispanic; MSM = men who have sex with men; IDU = male or female injection drug user. VL = viral load; ARV = antiretroviral therapy.